Thomas Cerny
President at Swiss Cancer League
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christian Brühlmann | M | - |
ProteoMediX AG
 ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | 14 years |
| Ralph Schiess | M | 46 |
ProteoMediX AG
ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | 14 years |
| Isaac Kobrin | M | 75 |
TOLREMO therapeutics AG
 TOLREMO therapeutics AG Miscellaneous Commercial ServicesCommercial Services TOLREMO therapeutics AG engages in discovering and developing therapies for treating cancer patients. The firm serves on academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. The company was founded by Stefanie Flückiger-Mangual, Wilhelm Krek, Karl-Heinz Altmann, Isaac Kobrin, and Emmanuel Savioz in March 2017 and is headquartered in Zurich, Switzerland. | 7 years |
| Thomas A. Gutzwiller | M | 63 |
University of St. Gallen
| 31 years |
| Bénédict G. F. Hentsch | M | 76 |
University of St. Gallen
| - |
| Ruedi Aebersold | M | - |
ProteoMediX AG
ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | 14 years |
| Michèle Florence Sutter-Rüdisser | M | 45 |
University of St. Gallen
| 16 years |
| Karl-Heinz Altmann | M | - |
TOLREMO therapeutics AG
TOLREMO therapeutics AG Miscellaneous Commercial ServicesCommercial Services TOLREMO therapeutics AG engages in discovering and developing therapies for treating cancer patients. The firm serves on academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. The company was founded by Stefanie Flückiger-Mangual, Wilhelm Krek, Karl-Heinz Altmann, Isaac Kobrin, and Emmanuel Savioz in March 2017 and is headquartered in Zurich, Switzerland. | - |
| Stefanie Flückiger-Mangual | F | - |
TOLREMO therapeutics AG
TOLREMO therapeutics AG Miscellaneous Commercial ServicesCommercial Services TOLREMO therapeutics AG engages in discovering and developing therapies for treating cancer patients. The firm serves on academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. The company was founded by Stefanie Flückiger-Mangual, Wilhelm Krek, Karl-Heinz Altmann, Isaac Kobrin, and Emmanuel Savioz in March 2017 and is headquartered in Zurich, Switzerland. | 7 years |
| Richard Ammer | M | 54 |
University of St. Gallen
| 23 years |
| Miriam Meckel | M | 56 |
University of St. Gallen
| - |
| Emmanuel Savioz | M | - |
TOLREMO therapeutics AG
TOLREMO therapeutics AG Miscellaneous Commercial ServicesCommercial Services TOLREMO therapeutics AG engages in discovering and developing therapies for treating cancer patients. The firm serves on academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. The company was founded by Stefanie Flückiger-Mangual, Wilhelm Krek, Karl-Heinz Altmann, Isaac Kobrin, and Emmanuel Savioz in March 2017 and is headquartered in Zurich, Switzerland. | 7 years |
| Thomas Rudolph | M | 62 |
University of St. Gallen
| 24 years |
| Anne van Aaken | M | - |
University of St. Gallen
| - |
| Claudia Dyckerhoff | M | 58 |
University of St. Gallen
| - |
| Dominique von Matt | M | - |
University of St. Gallen
| - |
| Simone Westerfeld | M | 49 |
University of St. Gallen
| 9 years |
| Andreas Wallnöfer | M | 63 |
TOLREMO therapeutics AG
TOLREMO therapeutics AG Miscellaneous Commercial ServicesCommercial Services TOLREMO therapeutics AG engages in discovering and developing therapies for treating cancer patients. The firm serves on academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. The company was founded by Stefanie Flückiger-Mangual, Wilhelm Krek, Karl-Heinz Altmann, Isaac Kobrin, and Emmanuel Savioz in March 2017 and is headquartered in Zurich, Switzerland. | - |
| Elgar Fleisch | M | 56 |
University of St. Gallen
| - |
| Patrick Stach | M | 64 |
University of St. Gallen
| - |
| Anna Sumeray | F | - |
ProteoMediX AG
ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | 3 years |
| Simona Scarpaleggia | F | 64 |
University of St. Gallen
| - |
| Peter Sester | M | - |
University of St. Gallen
| - |
| Solange Peters | M | - |
Swiss Cancer League
| 7 years |
| Oliver M. Bartholet | M | 58 |
University of St. Gallen
| 8 years |
| Franz Jaeger | M | 83 |
University of St. Gallen
| 52 years |
| Peter Athanas | M | 70 |
University of St. Gallen
| 25 years |
| Erich Greiner | M | - |
TOLREMO therapeutics AG
TOLREMO therapeutics AG Miscellaneous Commercial ServicesCommercial Services TOLREMO therapeutics AG engages in discovering and developing therapies for treating cancer patients. The firm serves on academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. The company was founded by Stefanie Flückiger-Mangual, Wilhelm Krek, Karl-Heinz Altmann, Isaac Kobrin, and Emmanuel Savioz in March 2017 and is headquartered in Zurich, Switzerland. | - |
| Thomas Werlen | M | - |
University of St. Gallen
| - |
| Christoph Franz | M | 64 |
University of St. Gallen
| 7 years |
| Harry Welten | M | 59 |
ProteoMediX AG
ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | 10 years |
| Anton Scherrer | M | 82 |
University of St. Gallen
| - |
| Marc Mogalle | M | 50 |
University of St. Gallen
| - |
| Andreas Hunziker | M | 66 |
University of St. Gallen
| - |
| Peter Gomez | M | - |
University of St. Gallen
| 19 years |
| Ruth Metzler-Arnold | F | 60 |
University of St. Gallen
| - |
| Hans Künzle | M | 63 |
University of St. Gallen
| - |
| Walter P. von Wartburg | M | 84 |
University of St. Gallen
| - |
| Friedrich Fahrni | M | 82 |
University of St. Gallen
| 24 years |
| Thomas Bieger | M | 63 |
University of St. Gallen
| 28 years |
| Christoph Lechner | M | 57 |
University of St. Gallen
| 20 years |
| Andreas Binder | M | 67 |
University of St. Gallen
| 11 years |
| Beat Bernet | M | 69 |
University of St. Gallen
| - |
| Markus Isenrich | M | 71 |
University of St. Gallen
| - |
| Manuel Ammann | M | 54 |
University of St. Gallen
| 21 years |
| Thomas Ladner | M | - |
University of St. Gallen
| - |
| Markus Kramer | M | 60 |
University of St. Gallen
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bob E. Patterson | M | 81 |
THERAMetrics holding AG
 THERAMetrics holding AG Pharmaceuticals: MajorHealth Technology THERAMetrics holding AG is an independent biotech company, which discovers drugs for patients suffering from rare diseases. The company was founded by Fabio Cavalli, Vera Cavalli, Patrick Pozzorini, Dorian Bevec and Michael von und zu Liechtenstein on February 9, 2001 and is headquartered in Stans, Switzerland. | - |
| Anette Waygood | M | - |
University of St. Gallen
| 12 years |
| Vera Cavalli | F | 56 |
THERAMetrics holding AG
THERAMetrics holding AG Pharmaceuticals: MajorHealth Technology THERAMetrics holding AG is an independent biotech company, which discovers drugs for patients suffering from rare diseases. The company was founded by Fabio Cavalli, Vera Cavalli, Patrick Pozzorini, Dorian Bevec and Michael von und zu Liechtenstein on February 9, 2001 and is headquartered in Stans, Switzerland. | 10 years |
| Roland Kaufmann | M | - |
University of St. Gallen
| 6 years |
| Andreas Hellmann | M | - |
University of St. Gallen
| 6 years |
| Stefano Robbiani | M | - |
University of St. Gallen
| 8 years |
| Philipp Bucher | M | - |
University of St. Gallen
| - |
| Markus Bruderer | M | - |
University of St. Gallen
| 6 years |
| Yves Sewo | M | - |
University of St. Gallen
| 6 years |
| Jan Klöppelt | M | - |
University of St. Gallen
| 7 years |
| Oliver Streuli | M | 36 |
University of St. Gallen
| 7 years |
| Alessandro Lanfranchi | M | - |
University of St. Gallen
| 6 years |
| David Gilli | M | - |
University of St. Gallen
| 6 years |
| Lynn Sarah Klingler | F | - |
University of St. Gallen
| 6 years |
| Sebastian Waldmann | M | - |
University of St. Gallen
| 6 years |
| Roman Hürlimann | M | - |
University of St. Gallen
| 5 years |
| Stefano L. Saeger | M | - |
University of St. Gallen
| 7 years |
| Clara Kröhn | F | - |
University of St. Gallen
| 5 years |
| Gabriel Wildberger | M | - |
University of St. Gallen
| 5 years |
| Alexander Bente | M | - |
University of St. Gallen
| 6 years |
| Maja Markowitz | F | - |
University of St. Gallen
| 8 years |
| Christian Ritzmann | M | - |
University of St. Gallen
| 6 years |
| Quentin Meyer | M | - |
University of St. Gallen
| 6 years |
| Christian Küpper | M | - |
University of St. Gallen
| 6 years |
| Johannes Reichel | M | 42 |
University of St. Gallen
| 7 years |
| Raffael Rupprechter | M | - |
University of St. Gallen
| 6 years |
| Christian Weigend | M | - |
University of St. Gallen
| 8 years |
| Simon Lussi | M | - |
University of St. Gallen
| 6 years |
| Peter Specht | M | - |
University of St. Gallen
| 3 years |
| Nadya Steiner | F | - |
University of St. Gallen
| 4 years |
| Monika Bütler | M | 63 |
University of St. Gallen
| 17 years |
| Ruggero Gramatica | M | 59 |
THERAMetrics holding AG
THERAMetrics holding AG Pharmaceuticals: MajorHealth Technology THERAMetrics holding AG is an independent biotech company, which discovers drugs for patients suffering from rare diseases. The company was founded by Fabio Cavalli, Vera Cavalli, Patrick Pozzorini, Dorian Bevec and Michael von und zu Liechtenstein on February 9, 2001 and is headquartered in Stans, Switzerland. | 3 years |
| Sascha Peier | M | - |
University of St. Gallen
| 5 years |
| Geoffrey West | M | 84 |
THERAMetrics holding AG
THERAMetrics holding AG Pharmaceuticals: MajorHealth Technology THERAMetrics holding AG is an independent biotech company, which discovers drugs for patients suffering from rare diseases. The company was founded by Fabio Cavalli, Vera Cavalli, Patrick Pozzorini, Dorian Bevec and Michael von und zu Liechtenstein on February 9, 2001 and is headquartered in Stans, Switzerland. | - |
| Alejandro Navarro | M | - |
University of St. Gallen
| 1 years |
| Christoph M. Reich | M | 50 |
University of St. Gallen
| 2 years |
| Gustav Nilsson | M | - |
University of St. Gallen
| 21 years |
| Robert Huber | M | 87 |
THERAMetrics holding AG
THERAMetrics holding AG Pharmaceuticals: MajorHealth Technology THERAMetrics holding AG is an independent biotech company, which discovers drugs for patients suffering from rare diseases. The company was founded by Fabio Cavalli, Vera Cavalli, Patrick Pozzorini, Dorian Bevec and Michael von und zu Liechtenstein on February 9, 2001 and is headquartered in Stans, Switzerland. | 3 years |
| Bernhard Birkhaeuser | M | - |
University of St. Gallen
| 2 years |
| Martin Locher | M | - |
University of St. Gallen
| 2 years |
| Eric Stöcklin | M | - |
University of St. Gallen
| 2 years |
| Louisa Blum | F | - |
University of St. Gallen
| 3 years |
| Matthias Weigend | M | - |
University of St. Gallen
| 3 years |
| Dominik Langenegger | M | - |
University of St. Gallen
| 6 years |
| Maximilian Vogl | M | - |
University of St. Gallen
| 4 years |
| Maximilian Buchner | M | - |
University of St. Gallen
| 4 years |
| Aurelia Maurath | F | - |
University of St. Gallen
| 3 years |
| Katrin Wollinger-Zepf | F | - |
University of St. Gallen
| 2 years |
| Julia Dannath-Schuh | M | 47 |
University of St. Gallen
| 1 years |
| Martin Lehmann | M | 57 |
University of St. Gallen
| 2 years |
| David Fuss | M | - |
University of St. Gallen
| 3 years |
| Tobias Küng | M | - |
University of St. Gallen
| 4 years |
| Patrizia Buser | F | - |
University of St. Gallen
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Thomas Cerny
- Personal Network
